An FDA advisory committee recommended that several peptides, including: BPC-157, TB-500, KPV, and MOTS-c, be considered for inclusion on the FDA’s 503A Bulks List.
If finalized by the FDA, this could provide a clearer regulatory pathway for licensed compounding pharmacies to continue preparing these peptides.
The FDA will make the final decision, but this is an encouraging step for patients and providers who value access to compounded peptide therapies.
The conversation around peptide therapy continues to evolve, and we’re committed to keeping you informed with accurate updates.
Still Have Questions?
Have questions about peptide therapy or whether it’s right for your health goals? Our clinicians are here to help!
📞 Contact us to schedule a consultation. 203-491-2999
